OXiGENE tillkännager offentliggörandet av prekliniska uppgifter om OXi4503
01 juin 2010 09h47 HE
|
Oxigene, Inc.
Södra San Francisco, Kalifornien, 1 juni, 2010 (GLOBE Newswire) -- OXiGENE,
Inc. (Nasdaq: OXGN) (Stockholm: OXGN), ett biopharma företag som strävar efter
att upptäcka och utveckla nya och förbättrade...
OXiGENE Announces Publication of Preclinical Data on OXi4503 Demonstrating Potent Anti-Leukemic Effects
27 mai 2010 08h00 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., May 27, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Announces Clinical Data to be Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology
18 mai 2010 16h00 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., May 18, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Reports First Quarter 2010 Financial Results
11 mai 2010 16h33 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Announces First Quarter 2010 Earnings Conference Call and Webcast
05 mai 2010 08h00 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., May 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer and...
OXiGENE Applies for Voluntary Delisting From the Stockholm Exchange
23 avr. 2010 02h00 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., April 23, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Regains Compliance With NASDAQ Listing Requirements
07 avr. 2010 02h00 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., April 7, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors
05 avr. 2010 08h00 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., April 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Going Concern Opinion On Its Audited Financial Statements for 2009
19 mars 2010 08h00 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., March 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Change to Board of Directors
15 mars 2010 08h00 HE
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...